Patient considerations in the management of chronic constipation: focus on prucalopride.

Patient Prefer Adherence · 2016 · PMC4970632 · PMID 27528801

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

of borderline significanceP =0.1so close (0.05 < p ≤ 0.1)

The 4 mg treatment dose was associated with significant acceleration of overall colonic transit at 24 hours, but observed differences for the overall treatment group vs placebo were of borderline significance ( P =0.1). 44 In patients with severe constipation referred to a tertiary care center, treatment with 4 mg of prucalopride was found to significantly improve stool consistency and time to first stool.

also in 1,681 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.